Investors

Home / Investors / Press Releases

CymaBay Therapeutics to Present at Two Investor Conferences in March

Download PDF

NEWARK, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the 29th Annual ROTH Conference, being held March 12-15, 2017 at the Ritz Carlton in Laguna Niguel, California, and the Oppenheimer 27th Annual Healthcare Conference, being held March 21-22 at the Westin New York Grand Central in New York City.

29th Annual ROTH Conference Presentation Details
Date: Monday, March 13
Time: 5:00pm Pacific Time
Location: Ritz Carlton, Laguna Niguel, CA
Webcast: http://ir.cymabay.com/events

Oppenheimer 27th Annual Healthcare Conference Presentation Details
Date: Tuesday, March 21
Time: 4:30pm Eastern Time
Location: Westin New York Grand Central, New York City, NY
Webcast: http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.  Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

For additional information about CymaBay visit www.cymabay.com.

Contact: 
Sujal Shah    
CymaBay Therapeutics, Inc.  
(510) 293-8800    
Investors@CymaBay.com 

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

Primary Logo

Source: CymaBay Therapeutics, Inc.